Bristol-Myers Squibb Company (BMY)
| Market Cap | 133.74B +42.9% |
| Revenue (ttm) | 49.19B +3.1% |
| Net Income | 9.28B +83.8% |
| EPS | 4.54 +82.7% |
| Shares Out | 2.04B |
| PE Ratio | 14.41 |
| Forward PE | 10.21 |
| Dividend | $2.52 (3.85%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 32,970,876 |
| Open | 66.12 |
| Previous Close | 65.31 |
| Day's Range | 64.14 - 68.10 |
| 52-Week Range | 42.52 - 68.10 |
| Beta | 0.22 |
| Analysts | Hold |
| Price Target | 65.67 (+0.31%) |
| Earnings Date | Jul 30, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $65.67, which is an increase of 0.31% from the latest price.
News
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger
TD Cowen analyst Steve Scala doesn’t see logic in combination of AstraZeneca (AZN) and Bristol Myers (BMY). If combined, AstraZeneca’s 2027-2032 sales growth would be diluted by two percentage points,...
Bristol-Myers stock: why AstraZeneca merger is unlikely to happen
Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According...
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
5 Things to Know Before the Stock Market Opens on Monday
Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over ...
Citi views report of AstraZeneca, Bristol Myers talks as surprising
Citi analyst Graham Parry is surprised by the Financial Times report of a potential merger between AstraZeneca (AZN) and Bristol Myers (BMY). The firm believes Astra’s pipeline is “best-in-sector” and...
AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the...
Bristol Myers price target raised to $70 from $66 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Bristol Myers (BMY) to $70 from $66 and keeps a Neutral rating on the shares. The firm updated models in…
AstraZeneca holds talks with US cancer drug developer in $400bn merger
Bristol Myers Squibb tie-up would be one of biggest-ever pharma deals and create world's fourth-largest drugmaker
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca
The merger would be one of the biggest pharma deals ever. AstraZeneca's market capitalization stood at $264 billion as of Friday's close, while Bristol Myers Squibb had a total valuation of $133 billi...
AstraZeneca drops 6% to $159.98 after report of Bristol Myers merger talks
05:01 EDT AstraZeneca (AZN) drops 6% to $159.98 after report of Bristol Myers (BMY) merger talks
Bristol Myers jumps 8% to $70.47 after report of AstraZeneca merger talks
05:02 EDT Bristol Myers (BMY) jumps 8% to $70.47 after report of AstraZeneca (AZN) merger talks
Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?
AstraZeneca shares fell more than 6% in early trading on Monday after reports emerged that the British pharmaceutical giant had held preliminary discussions with US-based Bristol Myers Squibb over a p...
AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks
If maintained until close, the decline would be the stock's biggest one-day percentage fall since the day of the 2024 U.S. presidential election.
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
AstraZeneca is reportedly in talks with U.S. peer Bristol Myers Squibb over a megadeal. If completed, a combined company could be valued at roughly roughly $400 billion.
AstraZeneca shares tumble 7% after reported Bristol Myers talks
AstraZeneca shares tumbled 7% in early trading on Monday following reports of talks between the European pharmaceutical giant and U.S.-based Bristol Myers Squibb , baffling investors and analysts.
AstraZeneca Falls, Bristol Myers Rises on Early Merger Talks for Potential $400B Deal
British drugmaker AstraZeneca ($AZN) and U.S.-based Bristol Myers Squibb ($BMY) are in early talks about a potential merger that could create a $400 billion pharmaceutical giant, according to the Fina...
AstraZeneca in discussions to combine with Bristol Myers for $400B, FT says
AstraZeneca (AZN) is in discussions to combine with Bristol Myers Squibb (BMY) in a deal valued at nearly $400B, Oliver Barnes, James Fontanella-Khan, Aaron Kirchfeld, and Arash Massoudi of The…
AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times. The megadeal would be one of the large...
AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports
UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb , the Financial Times reported on Sunday, citing people familiar with the matter.
Bristol Myers price target raised to $71 from $66 at BofA
BofA raised the firm’s price target on Bristol Myers (BMY) to $71 from $66 and keeps a Buy rating on the shares. After a “strong” Q2 the pipeline story remains…
Bristol Myers price target raised to $59 from $54 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Bristol Myers (BMY) to $59 from $54 and keeps a Neutral rating on the shares. Bristol Myers delivered a…
Bristol Myers price target raised to $73 from $67 at JPMorgan
JPMorgan raised the firm’s price target on Bristol Myers (BMY) to $73 from $67 and keeps an Overweight rating on the shares.
Bristol Myers price target raised to $75 from $72 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Bristol Myers (BMY) to $75 from $72 and keeps a Buy rating on the shares. While the Q2 beat raises…
Bristol Myers price target raised to $65 from $60 at Wells Fargo
Wells Fargo raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps an Equal Weight rating on the shares. Despite a “beat and raise” quarter,…